Feature

Servier and French drug safety agency found guilty on diet drug


 

Mediator should never have been authorized for use

In terms of the fraud charges, the prosecutor estimated that the losses incurred by the primary health insurance industry were in the region of several hundred million euros.

She argued that Mediator should never have been reimbursed, as “it should never have benefited from market authorization, which it received solely due to the fraudulent actions of the company.”

But because of the statute of limitations, this argument was not heard, explained Dr. Frachon, “and the same is true of conflicts of interest, where limitations led to them being discharged.

“We understand the legal difficulties, but it’s a shame in terms of the signal sent.”

“I hope the medical world will learn the lesson and not continue with ‘business as usual’ with people who are delinquents. I think it will be essential to restore public confidence,” concluded Dr. Frachon.

No conflicts of interest or funding were declared.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Semaglutide for meaningful weight loss in obesity and diabetes?
MDedge Endocrinology
Two popular screening tests for gestational diabetes clinically equivalent
MDedge Endocrinology
‘Major update’ of BP guidance for kidney disease; treat to 120 mm Hg
MDedge Endocrinology
Type 2 diabetes linked to increased risk for Parkinson’s
MDedge Endocrinology
High obesity rates in Southern states magnify COVID threats
MDedge Endocrinology
Diabetes prevention moves toward reality as studies published
MDedge Endocrinology
Women with PCOS at increased risk for COVID-19
MDedge Endocrinology
Comic books help explain type 1 diabetes to all ages
MDedge Endocrinology
STEP 4: Ongoing semaglutide treatment extends weight loss
MDedge Endocrinology
Use of complimentary and alternative medicine common in diabetes patients
MDedge Endocrinology